How to Suspect and Manage Hepatic Encephalopathy
Screen all patients with cirrhosis for hepatic encephalopathy regardless of liver function status, and immediately start lactulose 25 mL orally every 12 hours (titrated to 2–3 soft stools daily) plus systematic correction of precipitating factors, which alone resolves approximately 90% of cases. 1, 2
Clinical Suspicion and Screening
Who to Screen
- Screen every patient with cirrhosis, regardless of disease severity. 1
- Overt HE occurs in 30–45% of cirrhotic patients with an incidence of 20% per year, reaching 50% after TIPS placement. 1
- Covert HE affects more than two-thirds of patients, with some studies showing prevalence up to 85%. 1
Signs Strongly Suggestive of Overt HE
Systematically investigate for: 1
- Asterixis (flapping tremor)
- Psychomotor slowing
- Sleep–wake inversion
- Temporospatial disorientation
- Impaired consciousness
Grading System (West Haven Criteria)
- Grade I: Mild alterations in consciousness, subtle personality changes, decreased attention, sleep disturbances, irritability or apathy, difficulty with complex cognitive tasks. 2, 3
- Grade II: Mild disorientation (especially temporal), pronounced lethargy, inappropriate behavior, asterixis, dysarthric or slow speech. 2, 3
- Grade III–IV: Severe disorientation to coma; these patients cannot protect their airway. 2
Screening for Covert HE
- Use the animal naming test as the preferred bedside assessment tool. 1
- Interview patients and family about psychomotor slowing, sleep disorders, sleep–wake inversion, impaired calculation ability, and recent inability to perform previously routine tasks. 1
- Critical Flicker Frequency (CFF) test below 38 Hz suggests covert HE if available. 1
Immediate Management: Four-Pronged Approach
All patients with overt HE require simultaneous implementation of four steps: 2
- Stabilize altered consciousness and protect the airway
- Exclude alternative causes (intracranial hemorrhage, infection, metabolic derangements)
- Identify and correct precipitating factors (present in 80–90% of episodes)
- Start empirical lactulose immediately
Identification and Correction of Precipitating Factors
This is the cornerstone of management—correcting precipitating factors alone resolves HE in approximately 90% of patients. 2, 3
Systematic Evaluation and Treatment
| Precipitating Factor | Diagnostic Tests | First-Line Treatment |
|---|---|---|
| GI bleeding | Endoscopy, CBC, digital rectal exam, stool occult blood | Blood transfusion, endoscopic hemostasis, vasoactive medications [2] |
| Infection | CBC with differential, CRP, chest X-ray, urinalysis/culture, blood cultures, diagnostic paracentesis | Empiric broad-spectrum antibiotics immediately [2] |
| Constipation | Clinical history, abdominal plain radiograph | Enemas or osmotic laxatives [2] |
| Dehydration | Skin turgor, vital signs, basic metabolic panel | Hold diuretics, give IV albumin or isotonic fluids [2] |
| Electrolyte disturbances | Sodium, potassium, magnesium, phosphate | Correct sodium to 140–145 mmol/L; replete other electrolytes [2] |
| Renal dysfunction | BUN, creatinine, cystatin C, electrolytes | Adjust nephrotoxic drugs, optimize volume status [2] |
| Sedative medications | Medication review | Discontinue benzodiazepines, opioids, other CNS depressants [2,4] |
Pharmacologic Treatment
First-Line: Lactulose
- Start lactulose 25 mL orally every 12 hours. 2
- Titrate to achieve exactly 2–3 soft stools per day—not diarrhea. 2, 3
- Achieves clinical response in approximately 75% of patients. 2
- Underdosing leads to treatment failure; overdosing causes dehydration, hypernatremia, aspiration risk, and severe perianal irritation. 2
Second-Line: Rifaximin
- Add rifaximin 550 mg orally twice daily if patient has recurrent episodes despite lactulose or after a second overt episode. 2, 3
- Reduces HE recurrence risk by 58% (22.1% vs 45.9%; NNT = 4) and hospitalization risk by 31% (13.6% vs 22.6%; NNT = 9). 2
- Rifaximin should not be used as monotherapy for acute overt HE—evidence quality does not support it as first-line. 2
- Long-term rifaximin therapy (>24 months) is safe and well-tolerated. 2
Adjunctive Therapies for Refractory Cases
- Intravenous albumin 1.5 g/kg/day combined with lactulose improves clinical recovery within 10 days (75% vs 53.3%; p = 0.03) in grade ≥2 HE. 2
- Intravenous L-ornithine L-aspartate (LOLA) 30 g/day lowers HE grade within 1–4 days (odds ratio 2.06–3.04) and shortens recovery time by 0.6 days. 2
- Oral branched-chain amino acids (BCAAs) 0.25 g/kg/day may be used as adjuncts in patients unresponsive to standard therapy. 1, 2
- Polyethylene glycol (4 L over 4 hours) demonstrated superiority to lactulose alone, shortening median time to resolution to 1 day versus 2 days (p = 0.01); further trials are needed. 2
Agents NOT Recommended
- Neomycin and metronidazole carry significant risks: intestinal malabsorption, nephrotoxicity, ototoxicity (neomycin), and peripheral neuropathy (metronidazole). 2
Management by Encephalopathy Grade
Grades I–II (Mild-to-Moderate)
- Manage on a medicine ward with frequent mental status checks; ICU is preferable if available. 2, 3
- Transfer immediately to ICU if level of consciousness declines. 2, 3
- Avoid sedatives entirely—benzodiazepines and opioids worsen encephalopathy and have delayed clearance in liver failure. 2, 4
- Perform head CT to exclude intracranial hemorrhage, drug intoxication, or structural lesions. 1, 3
- Monitor glucose, potassium, magnesium, and phosphate levels closely. 3
Grades III–IV (Severe)
- Admit to ICU immediately. 2
- Perform immediate endotracheal intubation for airway protection—these patients cannot protect their airway and are at high risk of aspiration. 2, 4
- Elevate head of bed to 30°. 2
- Minimize stimulation and Valsalva-type maneuvers. 2
- Deliver lactulose via nasogastric tube if oral intake is impossible. 2, 4
- Lactulose enema protocol (when oral/NG administration is not feasible): 300 mL lactulose mixed with 700 mL water, administered 3–4 times daily, retained for at least 30 minutes. 2
- Treat seizures with phenytoin rather than benzodiazepines. 2, 4
- If intracranial hypertension develops: give IV mannitol 0.5–1 g/kg as a bolus (repeat once or twice if serum osmolality <320 mosm/L). 2
- Cerebral edema occurs in 25–35% of grade III patients and 65–75% of grade IV patients. 2
- Use low-dose propofol only if sedation is absolutely necessary—it may reduce cerebral blood flow. 2
- Dexmedetomidine (alpha-2 agonist) can reduce ventilation duration and preserve cognitive function. 4
Secondary Prophylaxis (Prevention of Recurrence)
Secondary prophylaxis with lactulose is mandatory after the first episode of overt HE—this is a Grade I, strong recommendation. 2, 3
- Continue lactulose indefinitely, titrated to 2–3 soft stools daily. 2, 3
- Add rifaximin 550 mg twice daily after a second episode or when recurrence occurs despite lactulose alone. 2, 3
- Without secondary prophylaxis, 50–70% of patients experience recurrence within one year. 2
- Prophylactic therapy may be discontinued only when precipitating factors are well-controlled (infections treated, variceal bleeding resolved, liver function significantly improved). 3
Role of Ammonia Testing
- A normal blood ammonia level should prompt reevaluation for alternative causes of altered mental status. 2, 3
- Elevated ammonia does NOT correlate with encephalopathy severity or prognosis and has limited utility beyond excluding HE when normal. 2, 3
- Routine ammonia level testing is not recommended for diagnosis of HE. 4
Nutritional Management
- Do not restrict protein—this worsens malnutrition and sarcopenia, which are risk factors for HE. 2
- Provide moderate hyperalimentation with small, frequent meals throughout the day. 2, 3
- Include a late-night snack. 2, 3
- Avoid fasting periods, which worsen HE. 2
- Multivitamin supplementation is generally recommended. 3
- Malnutrition is present in approximately 75% of patients with HE. 3
Differential Diagnosis and Exclusion of Alternative Causes
HE is a diagnosis of exclusion—altered mental status in cirrhotic patients should not be automatically attributed to HE. 4
Alternative Causes to Investigate
- Substance intoxication or withdrawal 4
- Drug-related issues (review all medications for hepatotoxicity and CNS effects) 4
- Infections (septic encephalopathy) 1, 4
- Electrolyte disorders (especially hyponatremia—maintain sodium >130 mmol/L) 4
- Intracranial hemorrhage 4
- Seizures 4
- Primary psychiatric disorders 4
- Renal dysfunction (uremic encephalopathy) 1
Diagnostic Imaging
- Perform non-contrast head CT to exclude intracranial hemorrhage, structural lesions, or other causes in all patients with new encephalopathy. 1, 2, 3
- Brain imaging should be done in every patient with chronic liver disease and unexplained alteration of brain function. 1
- EEG may show changes similar to HE in cases of renal dysfunction, hyponatremia, or septic encephalopathy. 1
Liver Transplantation Evaluation
- Evaluate for liver transplantation after the first episode of overt HE. 2, 3
- Recurrent, intractable overt HE with liver failure is a formal indication for liver transplantation. 2, 3, 4
- Overall survival after an overt HE episode is 42% at 1 year and 23% at 3 years. 1, 2
Discharge Planning and Follow-Up
Before Discharge
- Confirm neurological status and judge to what extent deficits are attributable to HE versus other neurological comorbidities. 1
- Inform caregivers that neurological status may change once acute illness settles and medication requirements could change. 1
- Recognize precipitating and risk factors for future HE development. 1
Patient and Family Education
- Effects of medication (lactulose, rifaximin) and potential side effects (e.g., diarrhea). 1
- Importance of adherence to lactulose therapy. 1
- Early signs of recurring HE (sleep disturbances, confusion, asterixis). 1
- Actions to take if recurrence: anticonstipation measures for mild recurrence; referral to general practitioner or hospital if HE with fever. 1, 4
Outpatient Monitoring
- Plan postdischarge consultations to adjust treatment and prevent reappearance of precipitating factors. 1
- Monitor neurological manifestations in patients with persisting HE to adjust treatment. 1
- Evaluate gait, walking, and risk of falls. 1
- Close liaison with family, general practitioner, and primary health service. 1
Critical Pitfalls to Avoid
- Failing to systematically search for precipitating factors, which cause 80–90% of cases. 2, 3
- Not titrating lactulose adequately to achieve exactly 2–3 stools per day. 2, 3
- Confusing HE with other causes of altered mental status without exclusion of alternative diagnoses. 2, 3, 4
- Not initiating secondary prophylaxis after the first episode. 2, 3
- Relying exclusively on ammonia levels for diagnosis, staging, or prognosis. 2, 3
- Restricting protein intake, which worsens outcomes. 2
- Using benzodiazepines, which have delayed clearance and exacerbate encephalopathy. 2, 4
- Initiating HE-specific therapy before establishing optimal standard care for at least 24–48 hours (unless within a placebo-controlled trial). 2
- Discontinuing proton pump inhibitors unless strictly necessary—they may contribute to bacterial overgrowth. 4